for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AnGes Inc

4563.T

Latest Trade

608.00JPY

Change

0.00(0.00%)

Volume

2,242,800

Today's Range

596.00

 - 

613.00

52 Week Range

303.00

 - 

1,350.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
608.00
Open
603.00
Volume
2,242,800
3M AVG Volume
80.74
Today's High
613.00
Today's Low
596.00
52 Week High
1,350.00
52 Week Low
303.00
Shares Out (MIL)
106.92
Market Cap (MIL)
65,010.44
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2019 AnGes Inc Earnings Release

Latest Developments

More

AnGes says exercise of options

AnGes says exercise of options

AnGes says exercise of options

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AnGes Inc

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

Industry

Biotechnology & Drugs

Contact Info

7-7-15 Saito-asagi

Saito Bio-Incubator 4 Fl.

+81.3.57302641

https://www.anges.co.jp/

Executive Leadership

Ei Yamada

President, Executive President, Chief Executive Officer of Subsidiaries, Representative Director

Tetsuya Ishihama

Executive Officer, Director of Clinical Development, Director of Medicine

Makoto Seki

Executive Officer, Chief Director of Business Planning

Kazuo Suzuki

Executive Officer, Director of Business Planning, Director of CMC Development, Director of Drug Discovery Research

Gen Watanabe

Executive Officer, Director of Research & Development Promotion, Director of Reliability Assurance

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
107.17
Price To Book (MRQ)
4.75
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-41.58
Return on Equity (TTM)
-40.27

Latest News

BRIEF-AnGes submits application for marketing approval for HGF gene therapy

* Says it submits application for marketing approval to Pharmaceuticals and Medical Devices Agency (PMDA) for HGF gene therapy for the treatment of critical limb ischemia (CLI)

BRIEF-AnGes submits CTN of hypertension DNA vaccine

* Says it submitted Clinical Trial Notification (CTN) of hypertension DNA vaccine to Therapeutic Goods Administration (TGA) in Australia

BRIEF-Anges MG says exercise of options

* Says 20,000 units of its 29th series options were exercised to 2 million shares of its common stock from June 10 to June 12

BRIEF-Anges expects to apply for approval to manufacture treatment for severe blockage of the arteries in the legs - nikkei

* Anges expects to apply in October for approval to manufacture and market treatment for severe blockage of the arteries in the legs - Nikkei Further company coverage:

BRIEF- Anges MG announces exercise of options through private placement

* Says 12,500 units of its 29th series options were exercised to 1.3 million shares of its common stock from June 1 to June 9, through private placement

BRIEF- Anges MG announces exercise of options

* Says 8,500 units of its 29th series options were exercised to 850,000 shares of its common stock from May 24 to May 31, through private placement

BRIEF-Anges MG receives IND approval from FDA

* Says it received investigational new drug (IND) approval from FDA, for a clinical trial with F-kappaB decoy oligo DNA in U.S, for treatment of discogenic lower back pain

BRIEF-AnGes MG plans cooperation with Vical Inc on development of genetic medication for Chronic Hepatitis B

* Says co enters into a cooperation contract with a US-based firm Vical Incorporated, on joint development of genetic medication for treatment of Chronic Hepatitis B

BRIEF-AnGes MG to change name to AnGes Inc

AnGes MG Inc: * Says it plans to change its name to AnGes Inc * Says the change will effective on July 1 Source text in Japanese: https://goo.gl/tUuvhR Further company Coverage: (Beijing Headline News)

BRIEF-AnGes MG announces exercise of 8,250 options

* Says 8,250 of 29th warrants were exercised into 825,000 shares of its common stock from Jan.5 to Jan. 12

BRIEF-AnGes MG announces exercise of 10,300 options

* Says 10,300 of 28th warrants were exercised into 1.03 million shares of its common stock from Sept. 26 to Sept. 28, including 150,000 shares at exercise price 258 yen, 200,000 shares at 242 yen and 680,000 shares at 234 yen per share

BRIEF-AnGes MG announces exercise of 13,681 options

* Says 13,681 of 28th warrants were exercised into 1.37 million shares of its common stock from Sept. 16 to Sept. 23, including 150,000 shares at exercise price 209 yen and 200,000 shares at 206 yen etc.

BRIEF-AnGes MG announces exercise of 22,500 options

* Says 22,500 of 28th warrants were exercised into 2.25 million shares of its common stock from Sep. 14 to Sep. 15, including 250,000 shares at exercise price 222 yen and 2 million shares at 214 yen

BRIEF-Anges MG announces exercise of options

* Says 8,700 of 28th warrants were exercised into 870,000 shares of its common shares from Sep. 7 to Sep. 13, comprised of 170,000 shares at exercise price 233 yen, 270,000 shares at 230 yen, 100,000 shares at 234 yen, 180,000 shares at 229 yen and 150,000 at 219 yen

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up